# PET with [18F]Flumazenil As an Index of Neurodegeneration in MS

> **NCT03825601** · NA · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 45 (actual)

## Conditions studied

- Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DIAGNOSTIC_TEST:** PET with [11C]Flumazenil

## Key facts

- **NCT ID:** NCT03825601
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825601, "PET with [18F]Flumazenil As an Index of Neurodegeneration in MS". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03825601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*